ImmunoCellular (IMUC) SPA from FDA 'Significant', Roth Capital Says

Roth Capital analyst Joseph Pantginis reiterated a Buy rating and $3 price target on ImmunoCellular Therapeutics (NYSE: IMUC) after the company announced the receipt of a Special Protocol Assessment (SPA) from the FDA for the pending start of the ICT-107 study in front-line glioblastoma.

"We believe this is a significant achievement for IMUC, which has been quite engaged with the regulatory authorities following the Phase II data showing the survival benefit in HLA-A2 patients," Pantginis said.

For an analyst ratings summary and ratings history on ImmunoCellular Therapeutics click here. For more ratings news on ImmunoCellular Therapeutics click here.

Shares of ImmunoCellular Therapeutics closed at $0.44 yesterday.

You May Also Be Interested In

• JPMorgan Starts Kanzhun Ltd (2076:HK) at Overweight
• Morgan Stanley Resumes OMV AG (OMV:AV) (OMVKY) at Equalweight
• Deutsche Bank Resumes Kloeckner & Co SE (KCO:GR) at Hold